Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HPN536 |
Synonyms | |
Therapy Description |
HPN536 is a tri-specific molecule that binds to and targets MSLN and CD3 epsilon (CD3e), as well as serum albumin, which redirects activated T-lymphocytes against MSLN-expressing tumor cells, potentially resulting in cell lysis (PMID: 33262134). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HPN536 | HPN-536|HPN 536 | MSLN Antibody 12 | HPN536 is a tri-specific molecule that binds to and targets MSLN and CD3 epsilon (CD3e), as well as serum albumin, which redirects activated T-lymphocytes against MSLN-expressing tumor cells, potentially resulting in cell lysis (PMID: 33262134). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03872206 | Phase Ib/II | HPN536 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Completed | USA | 0 |